Physician profile
Joseph Frederickson
NPI 1548883069
$1,744.05
in general payments reported to CMS, 2019-2025
23 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $31.25 · 2024: $594 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,725.20 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $784.78 | 2024-2025 | Fasenra, Tezspire, Breztri |
| Grifols USA, LLC | $145.98 | 2024-2025 | Prolastin-C Liquid |
| Amgen INC. | $84.70 | 2024-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.89 | 2025 | Ofev, Jascayd |
| Merck Sharp & Dohme LLC | $64.99 | 2024-2025 | Winrevair |
| Regeneron Healthcare Solutions, INC. | $64.27 | 2025 | Dupixent |
| Abiomed | $63.95 | 2024 | Impella |
| Jazz Pharmaceuticals INC. | $50.97 | 2024-2025 | |
| United Therapeutics Corporation | $50.92 | 2024-2025 | |
| Harmony Biosciences LLC | $41.98 | 2025 | |
| Electromed, INC. | $41.44 | 2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $35.99 | 2024-2025 | Uptravi, Opsynvi, Opsumit |
| Avadel Cns Pharmaceuticals, LLC | $31.93 | 2025 | Lumryz |
| Pharming Healthcare, INC. | $31.25 | 2023 | Ruconest |
| Glaxosmithkline, LLC. | $30.19 | 2024-2025 | Nucala |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $23.21 | 2025 | |
| Insmed, INC. | $22.24 | 2025 | Brinsupri, Arikayce |
| Pulmonx Corporation | $19.72 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Alexion Pharmaceuticals, INC. | $19.40 | 2024 | Ultomiris |
| Lilly USA, LLC | $14.88 | 2025 | Mounjaro |
| Axsome Therapeutics, INC. | $14.64 | 2025 | Sunosi |
| Viatris Specialty LLC | $13.92 | 2025 | Yupelri |
| Verona Pharma, INC. | $13.81 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Frederickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.